

# Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

---

MARIA ROUSSAKIS, MLT, MSC

PLATELET IMMUNOLOGY LABORATORY – MCMASTER UNIVERSITY



*Golden Horseshoe Education Supporting Transfusionists*

**GHEST**

# Case Study - Presentation

---

Pre-term neonate was born with severe thrombocytopenia ( $<10 \times 10^9/L$ ), causing bruising and bleeding.

A cord blood sample is sent for investigation of FNAIT, along with maternal and paternal blood samples.



Images retrieved from:  
[naitbabies.org](http://naitbabies.org)



*Golden Horseshoe Education Supporting Transfusionists*

**GHEST**

# Introduction

---

## Fetal and neonatal alloimmune thrombocytopenia (FNAIT):

- Incompatibility between fetal and maternal platelet antigens.
  - Stimulates production of maternal IgG antibody that crosses the placenta, causing fetal thrombocytopenia
- Occurrence of FNAIT ~1 in 1000 births



## Two goals in diagnostic testing for FNAIT:

1. Detect incompatibility between maternal and fetal platelet antigens by HPA genotyping.
2. Detect the presence of maternal platelet alloantibodies.



# Pathophysiology

- Human Platelet Antigens (HPAs) are expressed by the fetus as early as 16 weeks gestation.
- Fetal platelets can enter maternal circulation and alloimmunization occurs with the production of IgG antibodies against incompatible HPA type.
  - Antibodies cross the placenta and target fetal platelets, and are cleared by reticuloendothelial system.
- Most children affected by FNAIT do not have clinically significant bleeding.
  - However, 20% of cases result in intracranial hemorrhage
    - Fatal and can result in long-term neurological impairment
- Associated incompatible antigen is associated with the severity of the disease.
  - HPA-1a & -3 incompatibility: severe thrombocytopenia & bleeding
  - HPA-5a, -5b, -15a, & -15b: rarely cause severe disease



Golden Horseshoe Education Supporting Transfusionists

GHEST

# Question 1

---

Which of the following HPA antigen incompatibilities is the most common cause of FNAIT?

- a) HPA-1a
- b) HPA-3a
- c) HPA-5b
- d) HPA-15a

# Human Platelet Antigen (HPA)

- Antigens present on platelet surface glycoproteins.
- Polymorphisms due to single nucleotide change (SNP) or in-frame deletion.
- HPA genotyping performed using **PCR techniques**





Figure: Curtis & McFarland (2013)



# Laboratory Testing – DNA Extraction

- DNA extracted from maternal, paternal, and neonatal/fetal blood samples by solid phase extraction
  - Use spin columns for trapping DNA and removing contaminants
  - Buffers lyse cells in sample and precipitate DNA using ethanol (DNA is trapped in filter in spin column)
  - Wash buffer wash away contaminants
  - DNA is eluted in solution for long-term storage
- DNA concentration & purity:
  - Measure absorbance at 260 nm (for DNA) & absorbance at 280 nm (protein)
  - Ratio of A260/A280 determines purity
  - Optimal DNA purity: 1.8-2.0

# Question 2

---

What would result in a A260/A280 of 1.6?


- a) RNA contamination
- b) Protein contamination
- c) Incorrect buffers used
- d) Incorrect sample type



# Laboratory Testing – PCR & DNA Gel Electrophoresis



- Once DNA is extracted and the purity is determined, it can be amplified using SSP-PCR & visualized in DNA gel electrophoresis.
- Primers specific to the HPA polymorphisms anneal and amplified the DNA in a thermocycler
- After amplification, DNA is visualized on gel agarose electrophoresis based on length of product

Alleles	a	b	a	b	a	b	a	b	a	b	a	b	
Lanes	1	2	3	4	5	6	7	8	9	10	11	12	13





# Other Laboratory Techniques

## Bead Chip Microarray



## qPCR using Fluorescent Probes

### Fluorescent Probe-Based Real Time PCR (qPCR)



# Case Study - HPA Genotype Results

---

**Maternal genotype:** 1bb,2aa,3bb,5aa,6aa,9aa,15bb

**Paternal genotype:** 1aa,2aa,3ab,5aa,6aa,9aa,15bb

**Neonatal genotype:** 1ab,2aa,3bb,5aa,6aa,9aa,15bb

**Question 3: Are there incompatibilities between mother and neonate?**

# Case Study - HPA Genotype Results

---

**Maternal genotype:** 1bb,2aa,3bb,5aa,6aa,9aa,15bb

**Paternal genotype:** 1aa,2aa,3ab,5aa,6aa,9aa,15bb

**Neonatal genotype:** 1ab,2aa,3bb,5aa,6aa,9aa,15bb

# Laboratory Testing for Platelet Antibodies

---



## Platelet glycoprotein-specific assays

- Enzyme Linked Immunosorbent Assay (ELISA):
  - Commonly used
  - Easy to perform
  - Limitations: cannot detect new HPA antibodies, more costly
- Radioimmunoprecipitation (RIP):
  - Higher sensitivity
  - Can detect new antibodies
  - Limitations: cost, technical expertise required, handling radioactive materials



# Other Laboratory Techniques

## Monoclonal Antibody-Specific Immobilization of Platelet Antigen (MAIPA)



# Case Study - HPA Antibody Results

---

Based on testing performed by ELISA kit and in the RIP assay, **anti-HPA-1a** was detected in the **maternal** serum.

# Question 4

---

Which disease is considered the red cell counterpart to FNAIT?

- a) Autoimmune hemolytic anemia
- b) Drug-induced hemolytic anemia
- c) Delayed hemolytic transfusion reaction
- d) Hemolytic disease of the fetus and newborn



# HDFN vs. FNAIT

	HDFN	FNAIT
Maternal alloimmune sensitization of IgG antibodies	Yes	Yes
Fetal/neonatal symptoms	Anemia, cardiac failure, erythroblastosis fetalis	Thrombocytopenia, bleeding, intracranial hemorrhage
Are first pregnancies affected?	No	Yes
Screening programs available?	Yes	No

# Treatment

---

- IVIG
  - Women with infants previously affected with FNAIT:
    - Previous fetus with ICH: antenatal dose of IVIG 2 g/kg at 12-16 weeks
    - No previous fetus with ICH: antenatal dose of IVIG 1 g/kg at 20-26 weeks
  - Neonates:
    - IVIG 1 g/kg
- Platelets
  - Neonates:
    - To treat severe thrombocytopenia and/or bleeding
    - HPA antigen negative for antibody identified
      - If not readily available, random donor platelets can be given

# Case Study - Treatment

---

- In our case study, neonate was given three platelet transfusions
  - Not much improvement in platelet count
- IVIG given & platelet count improved drastically

## **Future pregnancies:**

- Mother closely monitored: IVIG given antenatally
- C-section: HPA-1bb platelets available

# Thank You!

## Neonatal Alloimmune Thrombocytopenia

W/ info from (Arnold, Smith, & Ksiazon, 2008)

### • What is it?


→ immune destruction of fetal platelets by maternal antibodies

### • Pathophysiology

→ During pregnancy, mother may become sensitized to **INCOMPATIBLE** paternal antigen on fetal platelets

→ Antibodies (IgG) produced in response

↳ **most common platelet antibodies**



\* once diagnosis of NAIT made, subsequent fetuses are at risk

\* genotype of fetus can be determined by amniotic fluid analysis


### Treatment

#### Antenatal mother

→ IVIG w/ or w/o steroids

#### Postpartum baby

- intravenous immune globulin (IVIG) w/ or w/o antigen compatible platelets
  - Antigen incompatible can be used if antigen compatible is not available
  - Components must be irradiated and should be CMV negative




### Risks?

- bleeding complications
- intracranial hemorrhage

### Diagnostic Testing

- testing maternal serum for platelet antibodies
- platelet genotyping on parental DNA



\* proving that father has antigen and mother has corresponding antibody

By @pathlabandrew & @medlabmaria